BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.
NICE has reversed its position on Johnson & Johnson's oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug.
Novartis' cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.
New guidance from NICE has rejected a combination regimen based on Johnson & Johnson's Darzalex for a group of previously-untreated patients with multiple myeloma, a type of bone marrow
Novartis' Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a